FILSPARI® (sparsentan) is for adults with primary igA nephropathy (igAN). See the possibilities with FILSPARI. Please see full Important Safety Information and the Medication Guide, …

INDICATIONS & USAGE FILSPARI ® (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease …

FILSPARI (sparsentan) was approved in February 2023 as a once-daily treatment to lower proteinuria in adults with primary IgA nephropathy. FILSPARI is a prescription medicine to …

Filspari is used for primary immunoglobulin A nephropathy (IgAN), to slow kidney function decline in adults at risk for worsening kidney disease. It is an oral tablet that is taken once a day. …

Filspari was approved for reducing proteinuria in people with primary IgAN based on preliminary (or interim) results from the PROTECT trial, which involved 134 medical practices in 18 countries.

Sparsentan (Filspari) is a medication used to reduce protein excretion in urine (proteinuria) in adults with primary immunoglobulin A nephropathy (IgAN), a progressive kidney disease. Do …

Learn more about FILSPARI®, the FDA approved treatment for adults with IgA Nephropathy (IgAN) and how it works to improve kidney function.

(April 12, 2023, New York, NY) — The National Kidney Foundation (NKF) will feature a late-breaking plenary session by Travere Therapeutics on the interim analysis of efficacy and …

WHAT IS IgA NEPHROPATHY (IgAN)? IgAN is a rare kidney disease IgAN is a leading cause of kidney failure. Loss of kidney function is permanent and may result in dialysis or transplant. …

FDA grants full approval to Filspari to slow kidney function decline in adults with primary IgA nephropathy at risk for disease progression.